Establishment Labs (NASDAQ:ESTA) Hits New 1-Year High – Should You Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $92.89 and last traded at $92.0310, with a volume of 45215 shares trading hands. The stock had previously closed at $90.62.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ESTA shares. Mizuho boosted their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. Citigroup increased their target price on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. BTIG Research restated a “buy” rating on shares of Establishment Labs in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Establishment Labs presently has an average rating of “Moderate Buy” and an average price target of $90.43.

Establishment Labs Stock Up 0.6%

The company has a market cap of $2.68 billion, a P/E ratio of -61.18 and a beta of 1.06. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a fifty day moving average price of $79.33 and a two-hundred day moving average price of $71.73.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) EPS. On average, research analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 255,000 shares of company stock valued at $18,144,896. Corporate insiders own 9.99% of the company’s stock.

Institutional Trading of Establishment Labs

A number of hedge funds have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after acquiring an additional 9,557 shares during the period. Geode Capital Management LLC raised its stake in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares in the last quarter. WINTON GROUP Ltd bought a new stake in Establishment Labs in the 2nd quarter worth approximately $651,000. Nebula Research & Development LLC grew its holdings in shares of Establishment Labs by 27.9% during the 2nd quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares during the last quarter. Finally, Sei Investments Co. lifted its position in Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after purchasing an additional 5,668 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.